Aster Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$399K Buy
+1,056
New +$369K 0.15% 233
2026
Q2
– Sell
-354
Closed -$86.2K – 869
2026
Q1
$86.2K Buy
+354
New +$102K 0.03% 355
2025
Q4
– Sell
-18
Closed -$5.05K – 1115
2025
Q3
$5.05K Sell
18
-279
-94% -$75.9K ﹤0.01% 806
2025
Q2
$71.7K Sell
297
-2,145
-88% -$507K 0.02% 559
2025
Q1
$648K Buy
+2,442
New +$735K 0.12% 236
2024
Q4
– Sell
-106
Closed -$35.5K – 1141
2024
Q3
$35.5K Buy
+106
New +$33.7K 0.01% 570

Other funds holding BIO

Aster Capital Management's BIO Position: Q3 2026 in Review

Aster Capital Management opened a new position in Bio-Rad Laboratories Class A (BIO) in Q3 2026: 1,056 shares worth $399K. The stake represents 0.15% of the portfolio and ranks #233 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in BIO as recently as Q1 2026.

Aster Capital Management first reported a position in BIO in Q3 2024 and has held it in 6 quarters since. The position peaked at $648K in Q1 2025. 417 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

  • Aster Capital Management held 1,056 shares of Bio-Rad Laboratories Class A worth $399K as of Q3 2026.
  • Bio-Rad Laboratories Class A was a new Aster Capital Management position in Q3 2026.
  • Bio-Rad Laboratories Class A made up 0.15% of Aster Capital Management's portfolio in Q3 2026, its #233 holding.
  • Aster Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2024 and has held it in 6 quarters since.
  • Aster Capital Management's Bio-Rad Laboratories Class A position peaked at $648K in Q1 2025.
  • 417 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.